Category: Intellectual property
-
Moderna, Biotech Partner on Non-Viral Genetic Drug Delivery
Two biotechnology companies are collaborating on creating genetic therapies delivered with lipid nanoscale particles using non-viral mechanisms to reach target cells.
-
Start-Up Licenses Protein Therapy Tech, Raises $50M
A new company making antibodies that degrade disease-causing proteins on and outside cell surfaces is raising $50 million in its first venture funding round.
-
Start-Up Licensing Antibody Eye Drops for Dry Eye Disease
An enterprise spun off from university labs is licensing its technology to a drug maker for eye drops with immune-system antibodies to treat dry eye disease.
-
Business-Academic Team to Create RNA Delivery for Cancer
A university lab and biotechnology company are developing new cancer treatments with therapies that stop RNA activity, delivered by advanced nanoscale particles.
-
Human Ovary Organoid Model Demonstrated, Licensed
A university lab created and licensed to a biotechnology company a model human ovary made of functioning cells for female reproductive health applications.
-
Start-Up Creating Software to Simplify Biomedical Analytics
A new enterprise began public operations to provide researchers with better analytical tools for making sense of mountains of complex genomics and related biomedical data.
-
Infographic – Chinese Companies Lead in A.I. Patents
Data in the chart are compiled by PatentSight, a service of LexisNexis, that show the seven leading holders of machine learning and other A.I. patents by company in 2017 and 2021.
-
Company Started for Gene Editing Rare Inherited Diseases
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells.
-
Peptide Discovery Company to Gain $3.3B in Licensing Deals
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion.
-
Biotech, Regeneron in $2B Cancer Antibody Deal
A developer of cancer treatments triggered by tumor chemistry is partnering with biologic drug maker Regeneron on dual-action cancer immunotherapies.